共 341 条
[1]
Wiviott SD(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 347-357
[2]
Raz I(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[3]
Bonaca MP(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657
[4]
Mosenzon O(2021)Sotagliflozin in patients with diabetes and recent worsening heart failure N Engl J Med 384 117-128
[5]
Kato ET(2021)Sotagliflozin in patients with diabetes and chronic kidney disease N Engl J Med 384 129-139
[6]
Cahn A(2019)Dapagliflozin in patients with heart failure and reduced ejection fraction N Engl J Med 381 1995-2008
[7]
Zinman B(2020)Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes JAMA 323 1353-1368
[8]
Wanner C(2020)Cardiovascular and renal outcomes with empagliflozin in heart failure N Engl J Med 383 1413-1424
[9]
Lachin JM(2021)Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 9 22-31
[10]
Fitchett D(2020)Dapagliflozin in patients with chronic kidney disease N Engl J Med 383 1436-1446